1.56 USD
↘ 0.17 (9.83%)AT CLOSE (11:59 AM EDT)
Outlook Therapeutics, Inc. Common Stock
OTLKNASDAQ • USD
1.58
↗ 0.02 (1.54%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
1.58
↗ 0.02 (1.54%)
Market: CLOSED
Outlook Therapeutics, Inc. Common Stock (OTLK) is currently trading at $1.57. OTLK shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (164.4%), a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, OTLK trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jul 15, 2026.
Open?$1.74
High?$1.77
Low?$1.56
Prev. Close?$1.73
Volume?9.7M
Avg. Volume?15.0M
VWAP?$1.63
Rel. Volume?0.65x
Bid / Ask
Bid?$1.58 × 700
Ask?$1.59 × 34.7K
Spread?$0.01
Midpoint?$1.59
Valuation & Ratios
Market Cap?231.8M
Shares Out?148.6M
Float?83.0M
Float %?99.9%
P/E Ratio?N/A
P/B Ratio?-7.99
EPS?-$0.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Employees
17
Market Cap
257.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-05-13
Address
111 S. WOOD AVENUE
ISELIN, NJ 08830
Phone: (609) 619-3990
ISELIN, NJ 08830
Phone: (609) 619-3990
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?64
Piotroski F-Score?0/9Weak
Altman Z-Score?-44.95Distress
Confidence?50%Low
Short InterestHigh
Short % of Float?16.88%High
Short Interest?14.0M
Days to Cover?1.0
Free Float83.0M
Avg Daily Volume15.9M
Settlement Date2026-06-30
Financial Health
Current Ratio?0.54Weak
Quick Ratio?0.45Weak
Cash Ratio?0.20Low
Debt/Equity?-0.93Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?-7.99CHEAP▾
S&P97
P/S?545.49HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-5.8CHEAP▾
S&P97
EV/Sales?590.73HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?164.4%STRONG▾
Peers50
S&P97
ROA?-217.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$251.0M
Fundamentals ratios updated end of day